Good Thank you, everyone. afternoon, Derek.
to We we're its on why and share opportunity to Longeveron's in confident you are future. update our progress pleased and
As developing reminder, cellular medicine Longeveron regenerative is for company our you those a to a newer story, therapy. cutting-edge of
with USD cellular billion a market lead XX development needs Lomecel-B, is pipeline represents potential a a USD candidate Our compound opportunity billion. approximately to product evaluated X U.S. therapy numerous important medical Addressing unmet called across and of being that opportunity XX treatment areas.
opportunity X Lomecel-B. confidence our are in ability to There reasons of achieve the that main me give
initial Alzheimer's II I Phase proprietary, that in Phase trials a foundation syndrome I is clinical strong or launch heart Lomecel-B a left and aging-related has results scalable trials disease, is HLHS. in trials. X cellular first Frailty, II our Phase allogeneic and own therapy and hypoplastic across I in and The of delivered positive science.
and manufacturing. of research experience across the regulatory and expertise advancing this our the possible which clinical team, of makes development, is launch Second own
the for is this most team's research -- the Third, to patients. commitment and advance fourth reason, the dedication and important
to syndrome, therapeutic lot they Frailty, heart fully have impact to disease, disease a so a their their lack left infant families. day of are They It solutions our aging for opportunity heart develop but a in lives an the drives starts memory devastating associated out working and express doctors, we What the see these unmet have and everyone patients surgery reasons for day these scientists year. after young an are early with to the is why the words needs. priority freely conditions these to and impact every impact, Longeveron, them. for for patients HLHS, and our drive impact heartbreaking my here at a convey to make can in in hopefully strategic and this that cognition Alzheimer's. on Alzheimer's These is and information Hypoplastic of X and confidence day the ability positive with
designation, ELPIS path we of this success end program ELPIS approval. probability produce treatment potential II, were evaluating we completed our the designation, as may The Completing highest review for HLHS Orphan valuable Rare basis results a for also with awarding upon initiating factor, priority U.S. study, X with ongoing Phase were FDA Pediatric approval of to is I priority to very Fast or data the a program is enrollment the focus NDA by to study, regulatory which Disease generally this been speed Phase granting the is designation, Drug us distinct for as designations. our and another has USD these lead believe the with basis to Longeveron which year potentially vouchers our program. trial you Track the another review the enable which company. million. in positive sell which HLHS assets, potential a know, have I, program top of of selling to ELPIS additional As HLHS. priority this the The FDA primary the of as price that and in BLA, adjunct II excess granted known of or up I voucher is XXX Lomecel-B shortest review it important
is with late trial clinical My the and year IIa earlier data regulatory in strength to this We our review this CLEAR for further program. mild from meeting the of about Alzheimer's MIND clinical important the point by FDA positive Phase science disease. future strategy continuing evidenced anticipate
and some will additional Our provide HLHS Officer, disease Nataliya Medical program this call. both details Alzheimer's on Dr. the Chief Agafonova, in later
I optimizing our take company our are just the to reinforces moment we highlight mentioned a want other resources, the X for where confidence. I of to that reason and areas
Lomecel-B and impairment preliminary we participants aging-related Frailty, enrolling aging-related Phase gaining Frailty, other receive that cognitive are our indications suggesting expense data the clinical with Bahamas. their safety for Eligible or clinical for registry Given are and disease potentially the real-world efficacy. in may address may Frailty followed problem II Lomecel-B at evidence and from currency trial own Alzheimer's associated then our investigational additional
program is that this an in initial the indicative of our it's important? the of data supports the First, for this first authorization Why strength investigational place.
data and able patients and safely in be to guiding administered trials been safety efficacy. we trial. this Lomecel-B. believe investigational collect clinical over are program this date understand potential real-world this will clinical profile to registry better registry has Lomecel-B for Lomecel-B important We across activity, that though data treatment in Second, development to trial, XXX
cost-neutral registry expense. manner on quarter registry trial do of data this the success trial launch an Finally participants investigational their the Building and plan so importantly, of to far, we we in osteoarthritis Bahamas year. to the own this are in so at this as able in a fourth generate
capabilities. is on area regard The manufacturing Longeveron's and in second expertise
We enable us experts rapidly that proprietary cell to have assembled therapies. approach and take to team of a technology improved develop systematic
X Science rooms, All clean and area Park products are FDA feet of and quality control Life square Technology room of and Miami based consists guidance. ISO of at space X feet square ancillary as facility in manufactured X,XXX as and space. on Our state-of-the-art development, warehouse X,XXX GMP well released process containing clean
this a the manufacture approved, full facility company a and demand the from manufacturing gives us do need additional to we and trial company's pharmaceutical clinical capabilities not use capacity are currently us commercial if This facility other presents for potentially, organizations. as Lomecel-B capacity. While facilities for for in scale, opportunity an -- expertise,
expand contract operation to of part resource optimization our as plan We overall strategy. manufacturing
needs, in revenue our team leads contract eliminating approximately $X of cost and running clinical $X and the reducing it's once manufacturing expand contract million already annual have up and million fully, first with the under not additional We this offset We the has experience capital but believe our final generate and area to comments, client. this potential preliminary to to the me allocation work secured started which initiative capital and the helping development spend.
Alzheimer's X% fund will HLHS As existing of can which and with discussion prior expense the quarter. disease our year-over-year. operating our for into capital. program our development I optimizing us continued fourth combined comments, shareholders' good raised With expenses April, resources In focused program the being my focus $XX.X hope see you on tightly stewards down of help balance from and regulatory we sheet, million, we are on control, are total
therapy potential Longeveron. future data, in Lomecel-B for HLHS team, multiple all support strength of date as Lomecel-B to patients on the medical indications. generated broad Alzheimer's of unwavering and give experienced and and data disease, and across me regenerative committed in the our a The The that focus confidence
call the the turn will to to an Nataliya? I that, provide update on With Dr. program. development Agafonova clinical
